IP Library › Granted Patent US 12,473,347
Granted Patent B2
US 12,473,347 · App. 17/356,411 · Granted Nov 18, 2025

Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells

Inventors: Hans G. Klingemann (Culver City, CA); Laurent H. Boissel (Culver City, CA); Abhijit Dandapat (Culver City, CA)
Assignee: ImmunityBio, Inc.
C07K14/70535A61K40/15A61K40/30A61K40/31A61K40/35A61K40/4224A61P35/04C07K14/5443C07K14/55C07K14/7051C07K16/2827C12N5/0646
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,347
App. No.
17/356,411
Granted
Nov 18, 2025
Kind
B2
Abstract

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

Claims (23)

1 . A method for killing a programmed death-ligand 1 (PD-L1) expressing cell, the method comprising:

contacting the PD-L1 expressing cell with a plurality of recombinant NK-92 cells that each express an anti-PD-L1 chimeric antigen receptor (CAR) and an Fc receptor,

wherein the PD-L1 expressing cell is a myeloid-derived suppressor cell (MDSC) or a tumor associated macrophage (TAM),

wherein the CAR has at least 90% sequence identity to SEQ ID NO: 15.

2 . The method of claim 1 , wherein each NK-92 cell further expresses an endoplasmic reticulum-retained IL-2 (erIL-2).

3 . The method of claim 1 , wherein the PD-L1 expressing cell is in a tumor microenvironment.

4 . The method of claim 1 , wherein the MDSC expresses CD14 or CD15.

5 . The method of claim 1 , wherein the TAM expresses CD68 and further expresses CD206, CD204, and/or CD163.

6 . The method of claim 2 , wherein the erIL-2 has the amino acid sequence of SEQ ID NO:7.

7 . The method of claim 1 , wherein the CAR has 100% sequence identity to SEQ ID NO:15.

8 . The method of claim 7 , wherein each recombinant NK-92 cell comprises a tricistronic nucleic acid.

9 . The method of claim 8 , wherein the tricistronic nucleic acid comprises SEQ ID NO: 11.

10 . A method for killing a tumor cell expressing PD-L1, the method comprising:

contacting the tumor cell with a plurality of recombinant NK-92 cells that express an anti-PD-L1 CAR and an Fc receptor, wherein the PD-L1 expressing cell is a myeloid-derived suppressor cell (MDSC) or a tumor associated macrophage (TAM),

wherein the CAR has at least 90% sequence identity to SEQ ID NO: 15.

11 . The method of claim 10 , wherein each NK-92 cell further expresses an erIL-2.

12 . The method of claim 11 , wherein the tumor cell is from a cancer selected from the group consisting of melanoma, breast cancer, ovarian cancer, gastric cancer, prostate cancer, squamous cell carcinoma, head and neck cancer, colon cancer, pancreatic cancer, uterine cancer, renal cell cancer, glioblastoma, medulloblastoma, sarcoma, and lung cancer.

13 . The method of claim 11 , wherein the erIL-2 has the amino acid sequence of SEQ ID NO:7.

14 . The method of claim 11 , wherein the contacting is performed in vivo.

15 . The method of claim 14 , further comprising contacting the PD-L1 expressing cell with an antibody.

16 . The method of claim 10 , wherein the CAR has 100% sequence identity to SEQ ID NO:15.

17 . The method of claim 16 , wherein each NK-92 cell comprises a tricistronic nucleic acid.

18 . The method of claim 17 , wherein the tricistronic nucleic acid comprises SEQ ID NO: 11.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
CHANGE OF NAME Recorded Aug 18, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057220/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2021
From: DANDAPAT, ABHIJIT; KLINGEMANN, HANS G.; BOISSEL, LAURENT H.
To: NANTKWEST, INC.
Reel/Frame 057145/0915 →
Continuity (3)
Division 16529159 · Aug 1, 2019
Provisional Application 62753740 · Oct 31, 2018
Related Publication 20210322477A1 · Oct 21, 2021
References Cited (84)
US 7618817B2 · Campbell · 2009 [cited by applicant]
US 8034332B2 · Klingemann · 2011 [cited by applicant]
US 8313943B2 · Campbell · 2012 [cited by applicant]
US 9150636B2 · Campbell · 2015 [cited by applicant]
US 9181322B2 · Campbell · 2015 [cited by applicant]
US 10138462B2 · Klingemann · 2018 [cited by applicant]
US 11077143B2 · Klingemann et al. · 2021 [cited by applicant]
US 20020068044A1 · Klingemann · 2002 [cited by applicant]
US 20130040386A1 · Campbell · 2013 [cited by applicant]
US 20180002424A1 · Belk et al. · 2018 [cited by applicant]
US 20180187149A1 · Ma et al. · 2018 [cited by applicant]
US 20180193383A1 · Lee et al. · 2018 [cited by applicant]
US 20190240258A1 · Li et al. · 2019 [cited by applicant]
US 20200129552A1 · Klingemann et al. · 2020 [cited by applicant]
US 20210315934A1 · Klingemann et al. · 2021 [cited by applicant]
CA 3094111A1 · 2020 [cited by applicant]
CN 107384870A · 2017 [cited by applicant]
CN 107709552A · 2018 [cited by applicant]
CN 112567024A · 2021 [cited by applicant]
JP 2021519602A · 2021 [cited by applicant]
KR 20170131569A · 2017 [cited by applicant]
KR 1020200119891A · 2020 [cited by applicant]
WO 9849268A1 · 1998 [cited by applicant]
WO 2006004518A1 · 2006 [cited by applicant]
WO 2016160602A2 · 2016 [cited by applicant]
WO 2016201304A1 · 2016 [cited by applicant]
WO 2017080377A1 · 2017 [cited by applicant]
WO 2017100709A1 · 2017 [cited by applicant]
WO 2018013975A1 · 2018 [cited by applicant]
WO 2018075989A1 · 2018 [cited by applicant]
WO 2018076391A1 · 2018 [cited by applicant]
WO 2019152513A1 · 2019 [cited by applicant]
WO 2019226708A1 · 2019 [cited by applicant]
WO 2020028656A1 · 2020 [cited by applicant]
WO 2020091868A1 · 2020 [cited by applicant]
Notice of Acceptance received for Australian Patent Application Serial No. 2019370094 dated Jan. 20, 2022, 3 pages. [cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2020556309 dated Nov. 2, 2021, 4 pages.(Including English Translation). [cited by applicant]
Zhang et al., “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”, Journal of Immunology Research, 2018, vol. 2018, No. 4263520, 11 pages. [cited by applicant]
Tang et al., “First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia”, American Journal Cancer Research, 2018, vol. 8, No. 6, … [cited by applicant]
First Examination Report received for Israel Patent Application Serial No. 277386 dated Nov. 28, 2021, 15 pages. (Including English Translation). [cited by applicant]
Examination Report No. 1 received for Australian Patent Application Serial No. 2019370094 dated Nov. 23, 2021, 3 pages. [cited by applicant]
Hodson Jen, “NantKwest Launches First-in-Class, First-in-Human Phase I Clinical Trial With a Targeted PD-L 1 t-haNK Cell Therapy in Patients with Solid Tumors”, Internet webpage, NantKwest, URL: https://nantkwest.com/na… [cited by applicant]
Jochems et al., “ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody”, International journal of cancer, 2017, vol. 141, pp. 583-593. [cited by applicant]
Morvan et al., “NK cells and cancer: you can teach innate cells new tricks”, Nature Reviews Cancer, 2016, vol. 16, pp. 7-19. [cited by applicant]
Boyerinas et al. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L 1 antibody, avelumab (MSB0010718C), on human tumor cells Cancer Immunol. Res. 3, 1148-1157. [cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/529,159 dated Mar. 23, 2020, 29 pages. [cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/529,159 dated Nov. 9, 2020, 21 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,159 dated Mar. 17, 2021, 13 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,159 dated Jul. 14, 2020, 18 pages. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/529,159 dated May 21, 2021, 20pages. [cited by applicant]
Swartz et al., “Tumor micro environment complexity: emerging roles in cancer therapy”, Cancer Research, 2012, vol. 72, No. 10, pp. 2473-2480 (Cited from Specification). [cited by applicant]
Herberman et al., “Natural killer cells: their roles in defenses against disease”, Science, 1981, vol. 214, pp. 24-30 (Cited from Specification). [cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”, Leukemia, 1994, vol. 8, No. 4, pp. 652-658 (Cited from Specification). [cited by applicant]
Bronte et al., “Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards”, Nature Communications, 2016, vol. 7, No. 12150, pp. 1-10 (Cited from Specification). [cited by applicant]
Eksioglu et al., “Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858”, Leukemia, 2017, 27 pages (Cited from Specification). [cited by applicant]
Kuang et al., “Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1”, The Journal of Experimental Medicine, vol. 206, No. 6, pp. 1327-1337 (… [cited by applicant]
Haynes et al., “Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-γ”, The Journal of Immunology, 2001, vol. 166, pp. 182-187 (C… [cited by applicant]
Cartellieri et al., “Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer”, Journal of Biomedicine and Biotechnology, 2010, vol. 2010, No. 956304, pp. 1-13 (Cited from Specification). [cited by applicant]
Konstantinidis et al., “Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells”, Experimental Hematology, 2005, vol. 33, No. 2, pp. 159-164 (Cited from Specification). [cited by applicant]
Garcia-Sanchez et al., “Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologou… [cited by applicant]
Stasi et al., “Inducible apoptosis as a safety switch for adoptive cell therapy”, The New England Journal of Medicine, 2011, vol. 365, No. 18, pp. 1673-1683 (Cited from Specification). [cited by applicant]
Morgan Richard A, “Live and let die: a new suicide gene therapy moves to the clinic”, Molecular Therapy, 2012, vol. 20, No. 1, pp. 11-13 (Cited from Specification). [cited by applicant]
Klingemann et al., “Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells”, Cancer Immunology, Immunotherapy, 1991, vol. 33, pp. 395-397 (Cited from Specification). [cited by applicant]
Genin et al., “M1 and M2 macrophages derived fromTHP-1 cells differentially modulate the response of cancer cells to etoposide”, BMC Cancer 2015, vol. 15, No. 577, pp. 1-14 (Cited from Specification). [cited by applicant]
Lu et al., “The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells”, The Journal of Immunology, 2017, vol. 198 (1 Supplement) 124.9, 5 pages (Cited from Specification). [cited by applicant]
Touati et al., “A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response”, Current Gene Therapy, vol. 14, No. 3, 1page (Cited from Spec… [cited by applicant]
Office Action received for Korean Patent Application No. 10-2023-7015968 dated Dec. 14, 2023, 8 pages (including English translation). [cited by applicant]
Office Action received for Japan Patent Application No. 2022-093726 dated Jan. 5, 2024, 07 pages (including English translation). [cited by applicant]
Office Action received for Japan Patent Application No. 2022-093726 dated Aug. 2, 2024, 08 pages (including English translation). [cited by applicant]
Office Action received for CN Application serial No. 201980023745.0 dated Jun. 20, 2024, 13 pages (including English translation). [cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3094111 dated Sep. 27, 2021, 4 pages. [cited by applicant]
Notice of Allowance received for KR Patent Application Serial No. 10-2020-7028887 dated Mar. 20, 2023, 12 pages. (Including English Translation). [cited by applicant]
Office Action received for KR Patent Application Serial No. 10-2020-7028887 dated Aug. 17, 2022, 08 pages. (Including English Translation). [cited by applicant]
Office Action received for KR Patent Application Serial No. 10-2023-7015968 dated Jun. 19, 2023, 07 pages. (Including English Translation). [cited by applicant]
Decision of Grant received for JP Patent Application Serial No. 2020-556309 dated May 10, 2022, 08 pages. (Including English Translation). [cited by applicant]
Office Action received for JP Patent Application Serial No. 2022-093726 dated Jul. 4, 2023, 12 pages. (Including English Translation). [cited by applicant]
Office Action received for IL Patent Application Serial No. 277386 dated May 4, 2022, 04 pages. (Including English Translation). [cited by applicant]
Notice of Acceptance received for IL Patent Application Serial No. 277386 dated Oct. 2, 2022, 06 pages. (Including English Translation). [cited by applicant]
Office Action received for IL Patent Application Serial No. 296408 dated Apr. 4, 2023, 08 pages. (Including English Translation). [cited by applicant]
First Exam Report received for AU Patent Application Serial No. 2022203822 dated Feb. 7, 2024, 03 pages. [cited by applicant]
Second Exam Report received for CA Patent Application Serial No. 3,094,111 dated Aug. 29, 2022, 03 pages. [cited by applicant]
Notice of Acceptance received for AU Patent Application Serial No. 2019370094 dated Jan. 20, 2022, 03 pages. [cited by applicant]
Notice of Allowance received for CA Patent Application Serial No. 3,094,111 dated Sep. 20, 2023, 01 page. [cited by applicant]
First office Action received for CN application serial No. 201980023745.0 dated Aug. 29, 2023, 15 pages (including English Translation). [cited by applicant]